BridgeBio (BBIO) Pharma announced that the U.S. Food and Drug Administration approved Attruby, an orally-administered near-complete stabilizer of Transthyretin, or TTR, for the treatment of adults ...
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a condition that can lead to the heart not pumping well. Attruby (acoramidis) was approved in 2024 by the FDA to treat people with ATTR-CM. It has ...
As with other drugs, Attruby (acoramidis) can cause side effects, such as diarrhea. If Attruby’s side effects become difficult to tolerate, talk with your doctor or pharmacist. Attruby (acoramidis) is ...
-Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR. Attruby has been shown to preserve the native function of TTR as a transport protein of ...
Near-complete in vitro TTR stabilization was observed as early as day 28 and through completion of a 30-month study of patients with ATTR-CM. The Food and Drug Administration (FDA) has approved ...
A BridgeBio Pharma drug developed for an increasingly prevalent cardiovascular condition has won FDA approval, marking a comeback for a company and a molecule with a turbulent history. But BridgeBio’s ...
Attruby’s recent approval positions BBIO as a direct competitor to PFE’s Vyndaqel in ATTR-CM. Attruby has a 42% reduction of heart failure risk with 90% TTR stabilization. So I think it could have a ...
Attruby has possible interactions with some other drugs and certain supplements. Examples include carbamazepine (Tegretol, others) and St. John’s wort. Talk with your doctor to avoid potentially ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback